<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0026986" disease_type="Neoplastic Process" abbrv="MDS">Preleukemic syndromes</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PLS</z:e>) evolve to <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) in 15-50% of cases, but rarely transform to <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (ALL) </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> following <z:e sem="disease" ids="C0026986" disease_type="Neoplastic Process" abbrv="MDS">preleukemic syndromes</z:e> has a poor prognosis, but little is reported about the outcome of secondary ALL </plain></SENT>
<SENT sid="2" pm="."><plain>From the adult <z:hpo ids='HP_0001909'>leukemia</z:hpo> database at MD Anderson <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Center, nine patients with ALL following <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) (n=6), smoldering <z:hpo ids='HP_0001909'>leukemia</z:hpo> (n=1), or cytopenias with dysplastic features (n=2) were identified </plain></SENT>
<SENT sid="3" pm="."><plain>Clinical and laboratory features were abstracted from the database, patient charts, review of the bone marrows and special laboratory studies </plain></SENT>
<SENT sid="4" pm="."><plain>The median interval from diagnosis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PLS</z:e> to ALL was 6 months </plain></SENT>
<SENT sid="5" pm="."><plain>Blasts with lymphoid <z:mp ids='MP_0000002'>morphology</z:mp> and terminal deoxynucleotidyltransferase (TdT) and <z:chebi fb="0" ids="29149">periodic acid</z:chebi> Schiff (<z:chebi fb="61" ids="27565">PAS</z:chebi>) staining were present in eight of nine cases and four of six cases respectively </plain></SENT>
<SENT sid="6" pm="."><plain>T cell and myeloid markers were expressed in the majority of cases, but T cell gene rearrangements were not detected </plain></SENT>
<SENT sid="7" pm="."><plain>Only one patient had electron microscopic myeloperoxidase-positive staining </plain></SENT>
<SENT sid="8" pm="."><plain>Two patients later transformed to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>Patients were predominantly male (89%) with a median age of 69 years </plain></SENT>
<SENT sid="10" pm="."><plain>The complete remission (CR) rate with ALL-directed chemotherapy (78%) was comparable to that of other <z:e sem="disease" ids="C0751606" disease_type="Neoplastic Process" abbrv="">adult ALL</z:e> patients (74%) (n=327) without excess <z:e sem="disease" ids="C0854467" disease_type="Disease or Syndrome" abbrv="">myelosuppression</z:e> </plain></SENT>
<SENT sid="11" pm="."><plain>Marrow <z:mpath ids='MPATH_589'>dysplasia</z:mpath> persisted in CR in three of seven cases </plain></SENT>
<SENT sid="12" pm="."><plain>The median remission duration of 16 months (range 4.5 to 51+ months) and the median overall survival of 21 months (range 1 to 55+ months) were comparable to that of ALL patients overall </plain></SENT>
<SENT sid="13" pm="."><plain>ALL following <z:e sem="disease" ids="C0026986" disease_type="Neoplastic Process" abbrv="MDS">preleukemic syndromes</z:e> is a distinct syndrome with T cell and myeloid markers and responds well to ALL-directed therapy </plain></SENT>
<SENT sid="14" pm="."><plain>The presence of myeloid and lymphoid markers suggests the transformation of an early stem cell </plain></SENT>
</text></document>